- Home
- QLGN vs KTTA Comparison
QLGN vs KTTA Comparison
Compare QLGN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- KTTA
- Stock Information
- Founded
- QLGN 1996
- KTTA 2020
- Country
- QLGN United States
- KTTA United States
- Employees
- QLGN 4
- KTTA N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- KTTA Health Care
- Exchange
- QLGN Nasdaq
- KTTA Nasdaq
- Market Cap
- QLGN 2.7M
- KTTA 3.5M
- IPO Year
- QLGN N/A
- KTTA 2021
- Fundamental
- Price
- QLGN $3.60
- KTTA $3.38
- Analyst Decision
- QLGN
- KTTA
- Analyst Count
- QLGN 0
- KTTA 0
- Target Price
- QLGN N/A
- KTTA N/A
- AVG Volume (30 Days)
- QLGN 226.0K
- KTTA 29.8K
- Earning Date
- QLGN 11-29-2024
- KTTA 11-13-2024
- Dividend Yield
- QLGN N/A
- KTTA N/A
- EPS Growth
- QLGN N/A
- KTTA N/A
- EPS
- QLGN N/A
- KTTA N/A
- Revenue
- QLGN N/A
- KTTA N/A
- Revenue This Year
- QLGN N/A
- KTTA N/A
- Revenue Next Year
- QLGN N/A
- KTTA N/A
- P/E Ratio
- QLGN N/A
- KTTA N/A
- Revenue Growth
- QLGN N/A
- KTTA N/A
- 52 Week Low
- QLGN $3.55
- KTTA $3.19
- 52 Week High
- QLGN $39.15
- KTTA $17.40
- Technical
- Relative Strength Index (RSI)
- QLGN 25.42
- KTTA 38.62
- Support Level
- QLGN $3.71
- KTTA $3.20
- Resistance Level
- QLGN $4.56
- KTTA $3.46
- Average True Range (ATR)
- QLGN 0.65
- KTTA 0.35
- MACD
- QLGN -0.06
- KTTA -0.01
- Stochastic Oscillator
- QLGN 2.08
- KTTA 16.38
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.